Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1

Keyphrases

• Human Immunodeficiency Virus Type 1 (HIV-1) 100%
• Protease 100%
• Protease Inhibitors 100%
• Molecular Clone 30%
• Nave 30%
• Virus 20%
• Reference Strain 20%
• Resistance mutations 20%
• Drug Susceptibility Testing 10%
• Publicly Available 10%
• Reduced Susceptibility 10%
• Replication Cycle 10%
• Patient-derived 10%
• Major Resistance 10%
• B Virus 10%
• Single Replication 10%
• Common Polymorphism 10%
• Main Determinants 10%
• N-terminal Region 10%
• Protease Substrate 10%
• Atazanavir 10%
• N-terminus 10%

Medicine and Dentistry

• Proteinase 100%
• Human Immunodeficiency Virus Type 1 Subtype B 100%
• Proteinase Inhibitor 100%
• Virus 30%
• Resistance Mutation 20%
• Amino Terminal Sequence 20%
• Drug Sensitivity 10%
• Atazanavir 10%
• Human Immunodeficiency Virus 1 10%

Immunology and Microbiology

• Human Immunodeficiency Virus Type 1 Subtype B 100%
• Virus 100%
• Amino Terminal Sequence 66%
• Human Immunodeficiency Virus 1 33%
• Drug Sensitivity 33%